Utilizing New Tools to Regulate Sleep-Wake Modes to Better Manage Insomnia

Activity Evaluation and Credit Application

Activity Post Test

Please note that to receive credit you must achieve a score of at least 70%.

Physicians: Certificate of Credit will be emailed within 4 weeks of successful completion of the activity.

Question Title

1. Orexin has been found to play a role in all of the following biological processes except:

Arousal

Stress response

Inflammation

Drug-seeking behavior

Question Title

2. Highly specific treatments of insomnia include all of the following except:

Cognitive behavioral therapy - insomnia

Suvorexant

Zolpidem

Prazosin

Question Title

3. Which of the following would be most appropriate to treat insomnia in a 42-year-old with sleep onset and sleep maintenance issues?

Norepinephrine antagonist (e.g., prazosin)

Selective melatonergic antagonist (e.g., ramelteon)

Selective H1 antagonist (e.g., doxepin)

Orexin receptor antagonist (e.g., suvorexant)

Question Title

4. Which of the following class would be most appropriate to treat insomnia in a 26-year-old with sleep-onset difficulty and a history of substance abuse?

Non-benzodiazepine (e.g., zolpidem)

Selective melatonergic antagonist (e.g., ramelteon)

Selective H1 antagonist (e.g., doxepin)

Antipsychotic (e.g., risperidone)

Question Title

5. Which of the following class would be most appropriate to treat insomnia in a 73-year-old with sleep-maintenance difficulty (particularly in the final third of the night)?

Selective H1 antagonist (e.g., doxepin)

Selective melatonergic antagonist (e.g., ramelteon)

Norepinephrine antagonist (e.g., prazosin)

Antidepressant (e.g., trazodone)

Question Title

6. In an analysis of wake bouts, the use of suvorexant was found to:

Reduce the number of short and long wake bouts

Reduce the number of long bouts and increase the number of short bouts

Increase the number of long and short bouts

Have no significant effect on the number of long or short wake bouts